<DOC>
	<DOCNO>NCT00369096</DOCNO>
	<brief_summary>The purpose study evaluate whether addition bemiparin , daily icodextrin solution peritoneal dialysis 16 week , increase peritoneal capacity ultrafiltration and/or reduces creatinine transport peritoneal dialysis patient present functional disorder relate ultrafiltration deficit and/or high transport .</brief_summary>
	<brief_title>Efficacy Study Addition Bemiparin Icodextrin Solution Peritoneal Dialysis Patients ( Bemidextrina )</brief_title>
	<detailed_description>Peritoneal dysfunction common complication patient stable treatment peritoneal dialysis . This peritoneal dysfunction define elevated creatinine transport lower standardized ultrafiltration capacity . The aim study evaluate efficacy addition bemiparin icodextrin solution patient peritoneal dialysis peritoneal transport disorder . The eligible patient randomly assign receive icodextrin solution bemiparin icodextrin solution without bemiparin .</detailed_description>
	<mesh_term>Peritoneal Diseases</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Patients 18 year old , either sex , give informed consent participate study . 2 . Patients stable treatment peritoneal dialysis 6 week present peritoneal dysfunction define capacity standardize ultrafiltration ( 3.86 % glucose maintain peritoneum 4 hour ) less 600 ml and/or elevate creatinine transport ( define D/P creatinine high 0.65 4 hour ) . 3 . Patients treat icodextrin solution peritoneal dialysis least one month inclusion . 4 . Patients remain dialyze liquid use PD contain glucose GDP ( glucose degradation product ) . 1 . Peritonitis past 2 month . 2 . Patients bleed time inclusion , patient history clinically evident bleed episodes and/or increase bleed due homeostatic alteration contradicts anticoagulant treatment and/or past two month present least one follow situation : active hemorrhage organic lesion susceptible bleeding ( e.g . active peptic ulcer , hemorrhagic cerebrovascular accident , aneurysms ) . 3 . Major surgery past month . 4 . Known hypersensitivity low molecular weight heparin ( LMWH ) , heparin substance porcine origin . 5 . Known hypersensitivity icodextrin . 6 . Patients treat systemic anticoagulation . 7 . Patients congenital acquire bleeding diathesis . 8 . Damage , surgical intervention , central nervous system , eye ear within past 2 month . 9 . Acute bacterial endocarditis slow endocarditis . 10 . Patients history heparinassociated thrombocytopenia . 11 . Patients hepatic insufficiency ( value AST and/or ALT &gt; 5 time normal value establish reference range local hospital laboratory ) . 12 . Severe arterial hypertension ( systolic blood pressure 200 mmHg and/or diastolic blood pressure 120 mmHg ) . 13 . Patients inability suspect inability comply treatment and/or complete study . 14 . Patients participate another clinical trial do past 30 day . 15 . Patients life expectancy le 6 month . 16 . Women pregnant , breastfeed fertile woman use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Bemiparin</keyword>
	<keyword>Icodextrin</keyword>
	<keyword>Peritoneal Transport Disorders</keyword>
</DOC>